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echocardiographyAbstract Background: Chronic obstructive pulmonary disease (COPD) is a common preventable
and treatable disease characterized by persistent airﬂow limitation that is usually progressive and
associated with an enhanced chronic inﬂammatory response in the airways and the lung to noxious
particles or gases. It has some signiﬁcant extra pulmonary effects that may contribute to its severity
in individual patient. Among COPD patients, cardiovascular diseases (CVD) are responsible for
approximately 50% of all hospitalizations and 20% of all deaths. Left ventricular diastolic dysfunc-
tion (LVDD) is a frequent condition in COPD patients. Inﬂammation is considered to be one of the
systemic manifestations of COPD and provides an alternative hypothesis to explain the relationship
between airﬂow limitation and cardiovascular risk. The present study aimed to assess the prevalence
of LV diastolic dysfunction in COPD patients and its relation to the disease severity and presence of
inﬂammatory markers.
Patient and methods: Forty nine (49) COPD patients were included in this study. All patients
were subjected to full medical history, physical examination, chest roentgenogram, spirometry, lab-
oratory blood testing for inﬂammatory mediators (C-reactive protein, matrix metalloproteinase-9
and tissue inhibitor metalloproteinase-1) and Echo Doppler study (conventional and tissue
Doppler analysis).
Results: The results showed that 36 COPD patients had LVDD (73.3%). There was a good
correlation between LVDD parameters and COPD severity across GOLD stages and inﬂammatory
markers. MMP-9 was statistically high in COPD patient with increasing severity with a
786 A.M. Rawy, D. Fathallap-value < 0.0001. Also LVDD parameters were correlated with MMP-9 (p-value < 0.00001).
Other inﬂammatory markers were also correlated to the degree of airway obstruction (FEV1)
and presence of LVDD.
Conclusion: There is a high prevalence of LVDD in COPD patients which is associated with
increased disease severity and associated with high levels of inﬂammatory markers (serum MMP-
9 and TIMP-1). It is important to exclude decompensated heart failure during COPD exacerbation.
ª 2015 TheAuthors. Production and hosting byElsevier B.V. on behalf of The Egyptian Society of ChestDiseases and
Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Background
Chronic obstructive pulmonary disease (COPD) is a common
preventable and treatable disease characterized by persistent
airﬂow limitation that is usually progressive and associated
with an enhanced chronic inﬂammatory response in the
airways and the lung to noxious particles or gases. It has
some signiﬁcant extra pulmonary effects that may contribute
to its severity in individual patient [1]. COPD is considered as
a major cause of respiratory morbidity and mortality world-
wide and reported to be fourth-leading cause of chronic
morbidity and mortality worldwide [2]. The best-recognized
comorbidities in COPD include lung cancer, cardiovascular
diseases, malnutrition involving primarily the loss and dys-
function of skeletal muscles, osteoporosis, anemia, diabetes,
increased gastroesophageal reﬂux, metabolic syndrome,
obstructive sleep apnea, depression, and anxiety [3].
Smoking triggers a local inﬂammatory response throughout
the whole tracheobronchial tree, and pathologic changes, a
characteristic of COPD, are found in the proximal large
airways, peripheral small airways, lung parenchyma, and
pulmonary vasculature. A part from these local effects,
smoking may signiﬁcantly contribute to or cause systemic
inﬂammation including the stimulation of the hematopoietic
system with polymorph nuclear leukocyte release, the
generation of systemic oxidative stress, and the endothelial
dysfunction of peripheral vessels. These systemic effects due
to smoking may account for the frequent concurrent presence
of other chronic illnesses such as cardiovascular diseases and
metabolic disorders in COPD patients [4].
Among COPD patients, cardiovascular diseases (CVD) are
responsible for approximately 50% of all hospitalizations and
20% of all deaths [5]. However, population-based studies have
suggested that regardless of smoking status, age or sex, a
COPD diagnosis increases the risk of cardiovascular morbidity
and mortality by approximately two folds [6]. Left ventricular
diastolic dysfunction (LVDD) is a frequent condition in
COPD patients. Inﬂammation is considered to be one of the
systemic manifestations of COPD and provides an alternative
hypothesis to explain the relationship between airﬂow limita-
tion and cardiovascular risk [7–9]. However, the prevalence
of LVDD in COPD patients according to inﬂammatory
markers and disease severity has not yet been established in
COPD patients [10]. Given the prognostic implications of
cardiovascular disease in COPD, its detection could serve as
a guide to appropriate treatment and eventually improve
survival.
Echocardiographic evaluation of left and right ventricular
function in patients with COPD is really challenging, mainly
due to lung hyperinﬂation but may be improved using tissueDoppler echocardiography (TDE) to study regional systolic
and diastolic function, myocardial and annular velocities to
allow precise and quantitative measurement of myocardial
function and can therefore detect subclinical changes [11].
COPD is a characterized by chronic inﬂammation with
increased levels of inﬂammatory markers as serum CRP and
matrix metalloproteinases (MMPs). MMPs are a family of
calcium-dependent, zinc-containing endopeptidases that are
structurally and functionally related [12]. They are secreted
in an inactive (latent) form, which is called a zymogen or a
pro-MMP. These latent MMPs require an activation step
before they are able to cleave extracellular matrix (ECM)
components [13]. Recent studies have shown that levels of
MMPs, especially MMP-9, are elevated in the bronchial
alveolar lavage (BAL) ﬂuid from patients with COPD,
compared to normal controls [14,15], and high levels of both
MMP-9 and its cognate inhibitor TIMP-1 have been found
in sputum from chronic bronchitis [16] and correlated with a
decrease in lung function [17,18]. MMP-9 may play important
physiologic roles in lung extracellular matrix remodeling and
repair, and in regulating the lung inﬂammatory response to
injury [19]. However, MMP-9 has also been implicated in the
pathogenesis of various lung diseases including chronic
obstructive pulmonary diseases [14,20,21].
The present study aimed to assess the prevalence of LV
diastolic dysfunction in COPD patients and its relation to
the disease severity and with high levels of inﬂammatory
markers (serum CRP, MMP-9 and TIMP-1).Patients and methods
Patients
Forty-nine (49) COPD patients were recruited from the
Pulmonary Outpatient Clinic aged >35 years. The severity
was categorized according to FEV1% of predicted referred to
GOLD classiﬁcation [1] to GOLD I (mild including 6 patients),
GOLD II (moderate including 25 patients), GOLD III (sever
including 15 patients) and GOLD IV (very sever including 3
patients). The exclusion criteria included a primary diagnosis
of other respiratory diseases e.g., asthma, restrictive disorders
(tuberculosis sequelae or interstitial ﬁbrosis), sleep
apnea/hypopnea syndrome or lung cancer. In addition, a pri-
mary diagnosis of unstable angina, congestive heart failure
(New York Heart Association class III or IV), atrial ﬁbrilla-
tion, previous diagnosis, treatment for or evidence of arterial
hypertension at the clinical examination and patients with sig-
niﬁcant valvular heart disease (more than mild aortic or mitral
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trolled diabetes mellitus, kidney or liver failure and cancer were
excluded. Participants who refused to take part in the study
were excluded.
The diagnosis of COPD was conﬁrmed according to the
guidelines established in the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) (1,12): a post-
bronchodilator FEV1/forced vital capacity (FVC) ratio
<0.70 and an increase <12% or 200 mL in FEV1 after
inhalation of a b2 agonist. COPD severity was categorized
according to the GOLD classiﬁcation, considering the
FEV1 (% predicted) into four grades. All of them have
FEV1/FVC < 70%. GOLD I is mild disease which has
FEV1P 80% of predicted, GOLD II (moderate) which has
50 6 FEV1 < 80% of predicted, GOLD III (sever) which
has 30 6 FEV1 < 50% of predicted and GOLD IV (very
sever) in which FEV1 < 30% of predicted [1].
Methods
All patients were subjected to full medical history, physical
examination, chest roentgenogram, spirometry, laboratory
blood testing for inﬂammatory mediators (C-reactive
protein, matrix metalloproteinase-9 and tissue inhibitor
metalloproteinase-1) and Echo Doppler study (conventional
and tissue Doppler analysis).
Pulmonary function tests
Before doing the test, ambient temperature and pressure were
entered with the patient data (age in years, weight in kilo-
grams, height in centimeters and sex) so that all results were
calculated as percent of predicted (% predicted) except for
FEV1/ FVC. Pulmonary function tests were done using
Sensor-medics V max series, 2130 spirometer,V 6200
Autobox, 6200 DL (Sensor Medics Corporation, 22705 Savi
Ranch Parkway Yorba Linda, 92887-4645 California, USA).
Flow/volume loop was performed to all cases pre and 15 min
after inhalation of 400 mcg salbutamol. FEV1 values were
expressed in liters and as percentages of FVC. Pulse oximetry
(SpO2) was assessed using an Onyx oximeter (Model 9500
Oximeter, Nonin Medical Inc., Minneapolis, MN, USA) while
the patients were breathing room air.
Echocardiographic analysis
Transthoracic echocardiography (Vivid 7; GE Healthcare) was
performed by one operator blinded to all other patient data.
With participants positioned in the left lateral decubitus and
monitored using an electrocardiographic lead, images were
obtained from the parasternal views (long axis and short axis),
the apical four-chamber view, and the subcostal view. All
of the measurements were performed in accordance with
the American Society of Echocardiography/European
Association of Echocardiography recommendations [22]. All
measurements were performed at end expiration as follows:
(1) Right ventricle dimensions, measured in apical view. (2)
Left ventricle size and wall thickness, measured in parasternal
view. (3) Left atrial diameter, measured in parasternal view.
Left atrial (LA) volume in systole was also measured just
before the mitral valve opening, using the biplane Simpson’smethod, as a mean between the values recorded in apical
four- and two-chamber approaches. Subsequently, LAV was
indexed for body surface area (BSA), such as left atrial volume
index (LAVI) in mL/m2 [23,24]. (4) Aortic root diameters,
measured at the sinuses of Valsalva. (5) Left ventricular
ejection fraction, assessed by Simpson’s rule when adequate
two- and four-chamber views were available, Or by measuring
the ejection fraction (EF) according to the Teichholz method.
In other cases we applied visual estimation (‘‘eye-balling’’). (6)
Evaluation of left ventricular diastolic function, which
included: (i) peak velocity of early diastolic ﬂow (E), peak
velocity of atrial contraction (A), and their ratio (E/A),
measured over the mitral valve. (ii) Tissue Doppler imaging
measured in the lateral mitral annulus at early diastole (e1),
in septal mitral annulus during diastole (e2), average mitral
annular velocity during diastole average (e), and the E/e ratio
[22]. (iii) Diastolic function of the left ventricle was classiﬁed
into four categories: normal; mild or grade I (impaired relax-
ation) pattern), moderate or grade II (pseudo normal ﬁlling),
and severe (restrictive) ﬁlling) or grade III diastolic dysfunc-
tion, following the practical approach scheme for grading dias-
tolic dysfunction according to the combined European and
American recommendations for the Evaluation of Left ventric-
ular diastolic function by echocardiography [22]. (7) Tricuspid
regurgitant velocity (TRV) recorded by continuous wave
Doppler. Pulmonary hypertension was considered when
TRV wasP 2.8 m s1 [22], and subsequently graded as mild
(2.8–3.4 m s1) or moderate–severe (>3.4 m s1) (Fig. 1).
Laboratory analysis
All samples were collected and analyzed at the same time.
Serum concentrations of MMP-9 and TIMP-1 were assayed
using the same batch of a commercially available kit (The
Ray Bio_ human MMP-9 and TIMP-1, 3607 Parkway Lane,
Suite 100 Norcross, GA 30092) using ELISA (enzyme-linked
immunosorbent assay). It is an in vitro enzyme-linked
immunosorbent assay for the quantitative measurement of
human MMP-9 and TIMP-1 respectively. The detection reac-
tion uses a modiﬁed pro-urokinase in which the activation
sequence, normally recognized by plasmin (Pro-Arg-Phe-Lys
b Ile-Ile-Gly-Gly), is replaced by a sequence speciﬁcally recog-
nized by MMPs (Arg-Pro-Leu-Gly b Ile-Ile-Gly-Gly). The
procedure was done according to manufacturer’s instruction.
The results were detected from slandered curve with minimum
detection value of 10 pg/ml for MMP-9 and 40 pg/ml for
TIMP-1. The CRP- latex agglutination test was used for the
qualitative and semi-quantitative detection of the CRP in
human serum for all patients. Latex particles coated with
IgG anti-human CRP were agglutinated when mixed with
samples containing CRP. The CRP-latex sensitivity was
calibrated to the Reference material CRM 470/RPPHS.
Statistical analysis
Patients’ characteristics and data were presented as
mean ± standard deviation unless otherwise stated.
Comparisons were performed by unpaired t-tests for quantita-
tive data .We performed analysis of variance (ANOVA) for
linear trend to analyze the differences inﬂammatory markers
and echodoppler variables across the GOLD stages. Pearson
Figure 1 Tissue Doppler imaging, measured early diastolic mitral annular wave in the lateral mitral annulus at early diastole (e1) Left
picture, early diastolic mitral annular wave in septal mitral annulus during diastole (e2), average mitral annular velocity during diastole
average (e).
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between of lung function and echo doppler variables and
inﬂammatory markers. P-value of <0.05 was used to indicate
differences between the groups that were statistically signiﬁ-
cant. Data analysis was performed with a commercially
available statistical analysis software package (SPSS 16.0 for
Windows; SPSS; Chicago, IL, USA).
Results
Forty-nine consecutive stable COPD patients were included in
this study from the outpatient department after exclusion of
other COPD who did not ﬁll the inclusion criteria. Those
patients were classiﬁed according to GOLD classiﬁcations to
GOLD I, II, III and IV. This study included forty-two male
patients and seven female patients. The mean age for all
patients was 53.6 ± 9.6. Age and sex did not differ statistically
between the groups. As the severity of COPD increased, the
spirometric values became lesser with highly signiﬁcant differ-
ences between groups. Inﬂammatory markers were statistically
highly signiﬁcantly different between COPD groups (Table 1).Table 1 Demographic, spirometric variables and inﬂammatory ma
Variables All patients
(n= 49)
COPD I
(n= 6)
C
(n
Sex M/F 42 /7 6/0 1
Age in years
Mean ± SD
53.6 ± 9.6 49.7 ± 10.7
Pulmonary function tests: (spirometry) Mean ± SD
FEV1/FVC 63.64 ± 7.7 69.2 ± 1.8
FVC (L) 2.96 ± 1.03 3.7 ± 0.83
FVC (%) 69.9 ± 17.4 88.2 ± 16.9
FEV1 (L) 1.98 ± 0.77 2.9 ± 0.76
FEV1 (%) 57.66 ± 17.03 86.8 ± 7.2
SpO2 95.53 ± 2.27 98.2 ± 0.75
c-reactive protein 9.3 ± 3.9 5.9 ± 1.05
Serum MMP-9
Mean ± SD
239.16 ± 43.27 191.3 ± 7.8 2
Serum TIMP-1
Mean ± SD
150.327 ± 33.8 178.3 ± 8.4 1
MMP-9/TIMP1 1.79 ± 0.92 1.07 ± 0.34
Mean ± SDEchocardiographic variables of systolic and diastolic func-
tions of the patients across GOLD classes are presented in
Table 2 with comparison between patients with GOLD I, II
31 patients (63.26%) in one group and III and IV 18 patients
(36.73%) in the other group, patients with severe and very sev-
ere COPD have statistically signiﬁcant higher LA volume,
lower E/A ratio, lower average (e) values and lower E/e ratio
if compared with patients with mild and moderate COPD
(Table 2).
The results in Table 3 show that 36 COPD patients had
LVDD (73.3%) with 18 patients (72%) in group 2, 15 patients
(100%) in group 3 and 3 patients (100%) in group 4 (Table 3).
They were divided according to LVDD severity to three
grades. There were 21 patients with grade I diastolic dysfunc-
tion most of them with COPD II patients. Grade II LVDD
including 12 patients and grade III LVDD was present in 3
patients (Table 4).
The results in Table 5 demonstrate that these echo variables
have statistically signiﬁcant correlations with FEVI across the
GOLD stages and the average e values correlate the best with
FEVI. For inﬂammatory markers, MMP-9 was statisticallyrkers of COPD patients according to the GOLD classiﬁcation.
OPD II
= 25)
COPDIII
(n= 15)
COPD IV
(n= 3)
p-Value
9/6 14/1 3/0
55.1 ± 9.7 51.9 ± 9.6 57.3 ± 5.5 0.5
64.6 ± 6.4 62.98 ± 7.2 48.1 ± 9.9 <0.0001
3.2 ± 1.1 2.4 ± 0.78 2.2 ± 0.42 0.01
75.8 ± 13.8 56 ± 10.1 52.9 ± 13.3 <0.0001
2.14 ± 0.67 1.51 ± 0.41 1.05 ± 0.02 <0.0001
63.4 ± 7.5 42.2 ± 4.8 28.9 ± 0.75 <0.0001
96.7 ± 1.15 93.5 ± 0.64 91 ± 1 <0.0001
8.4 ± 1.23 10.7 ± 1.4 14.3 ± 1.12 <0.0001
24.8 ± 30.3 270.4 ± 36.8 298 ± 47.5 <0.0001
62.6 ± 24 127 ± 33.2 108 ± 38.9 <0.0001
1.5 ± 0.45 2.4 ± 1.035 3.12 ± 1.53 <0.0001
Table 2 Echocardiographic variables of systolic and diastolic functions of the patients according to COPD severity.
Echo variables All patients (n= 49) COPD I/II (n= 31) COPD III/IV(n= 18) t-test p-Value
EF% Mean ± SD 60.14 ± 5.25 60.4 ± 5.8 59.8 ± 4.3 2.55 0.014
LA Volume ml/m2
Mean ± SD 35.76 ± 2.62 35.71 ± 2.75 35.8 ± 2.5 3.35 0.002
E/A Mean ± SD 0.93 ± 0.44 0.92 ± 0.38 0.91 ± 0.5 0.79 0.43
Average (e): Mean ± SD 7.16 ± 1.77 7.4 ± 1.7 6.8 ± 1.8 2.37 0.02
E/e: Mean ± SD 7.8 ± 5.6 7.6 ± 2.5 7.1 ± 3 2.59 0.03
EF: ejection fraction, E-wave: peak ﬂow velocity of early diastolic ﬁlling, A wave = peak ﬂow velocity of late atrial ﬁlling, Average e= average
mitral annular tissue Doppler, E/e peak ﬂow velocity of early diastolic ﬁlling/average mitral annular tissue Doppler velocities.
Table 3 Morphological echocardiographic evaluation of the patients according to COPD severity.
Echo variables COPD I (n= 6) COPD II (n= 25) COPDIII (n= 15) COPD IV (n= 3) Total
Normal echocardiogram 6 (100%) 7 (28%) 0 (0%) 0 (0%) 13 (26.5%)
Left atrial enlargement 4 (66.7%) 19 (76%) 12 (80%) 3 (100%) 38 (77.6%)
Diastolic dysfunction 0 (0%) 18 (72%) 15 (100%) 3 (100%) 36 (73.5%)
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of LVDD. There was a negative correlation of MMP9 and the
ratio of MMP9/TIMP1 with FEV1 while there was a positive
correlation of FEV1 and TIMP1 with a high statistical signif-
icant difference (Table 5).
The results in Table 6 shows there is a high statistical signif-
icant correlation between echo variables and inﬂammatory
markers, the E/e ratio correlates the best with MMP9 and
the ratio of MMP9/TIMP1 and TIMP-1 (Table 6).
Discussion
Cardiovascular disease is a frequent cause of mortality in
COPD. Roughly 30% of COPD patients die from a cardiovas-
cular cause [25–28]. The main ﬁndings in the current study are
that there was a high prevalence (73%) of LVDD in COPD
patients which is associated with increased disease severity
according to GOLD classiﬁcation and the presence of inﬂam-
matory markers serum MMP-9 and TIMP-1 while in other
studies the prevalence was 90% [29], 50% [30] and 64% [28].
In other study the prevalence was 47.5% [31]. The difference
in prevalence could be attributed to different numbers of
patients and severity of disease included in each study, use of
tissue Doppler for assessment of diastolic function in our study
which is more accurate in detection of LVDD than conven-
tional Doppler study used in other studies, also we excludedTable 4 Grades of LVDD in relation to grades of COPD.
Grades
of
LVDD
Grades of COPD
COPD I
(n= 6)
COPD II
(n= 25)
COPD III
(n= 15)
COPD
IV
(n= 3)
Total
Grade I 0 13 7 1 21
Grade II 0 5 6 1 12
Grade III 0 0 2 1 3
Total 0 18 15 3 36patients with known hypertension or uncontrolled diabetes
which is a well-known etiology of diastolic dysfunction.
The mechanisms that might explain the presence of left
ventricular diastolic dysfunction in COPD patients are many.
First is chronic hypoxemia leading to intracellular calcium
transport disturbances which might result in abnormalities of
myocardial relaxation [32,33]. This mechanism usually occurs
in severe cases of COPD, grade III and IV as shown in the cur-
rent study (Table 1). Second is the presence of pulmonary
hypertension with chronic right ventricular hypertrophy which
may develop in COPD patients followed by right ventricle
dilatation [34,35].
During early diastole, the ventricular septum displaces
toward the left ventricular cavity and the left ventricle becomes
distorted from its circular conﬁguration. The severity of left
ventricular and septal deformity depends on the transseptal
pressure gradient [30]. Thirdly, the presence of emphysema
and hyperinﬂation which has been related to impaired left
ventricle ﬁlling [36,37]. This is due to increased intrathoracic
pressures which may impair cardiac function by decreasing
biventricular preload and increasing left ventricular afterload
[38]. The fourth cause is the inﬂammation which is considered
to be one of the systemic manifestations of COPD [39]. In
the present study systemic inﬂammation was evaluated by
measuring C-reactive protein, MMP-9, TIMP-1 and MMP-9/
TIMP-1. There was a tendency towards higher MMP-9 and
CRP levels with higher GOLD-stage (Table 1). Indeed there
were lower levels of TIMP-1 and the ratio of MMP-9/TIMP-1
with higher gold stage. There was a statistically highly signiﬁ-
cant difference of inﬂammatory markers between COPD
grades and with increasing severity of disease. This ﬁnding
could explain that MMP-9 is involved in the disease process
in COPD [40]. MMP-9 has been implicated in human emphy-
sema, with its principal effect being the destruction of the
extracellular matrix, particularly elastin [41]. The protease:
antiprotease hypothesis has dominated thinking regarding
the pathogenesis of emphysema. CRP is the well-studied bio-
marker of systemic inﬂammation in COPD [42].
Although the majority of patients in the current study
with LVDD have mild diastolic dysfunction (type 1 diastolic
Table 5 Correlation coefﬁcient between Echo variables and FEV1.
Echo variables FEV1
All patients (n= 49) COPD I /II (n= 31) COPD III/IV (n= 18)
R p-Value r p-Value R p-Value
LA Volume ml /m2 0.53 <0.0001 0.16 0.2 0.2 0.3
E/A 0.13 0.0001 0.01 0.5 0.006 0.5
Average (e) 0.67 0.001 0.01 0.5 0.103 0.34
E/e 0.49 <0.001 0.2 0.1 0.06 0.4
MMP-9 0.77 0.0001 0.7 0.00004 0.3 0.09
TIMP-1 0.69 <0.0001 0.6 0.0001 0.16 0.3
MMP9/ TIMP1 0.64 0.0003 0.7 0.00004 0.2 0.17
CRP 0.02 0.4 0.9 0.00001 0.9 0.000001
Table 6 Correlation coefﬁcient between echo variables and inﬂammatory markers.
Echo variables MMP-9 TIMP-1 MMP9/TIMP1
R p-Value R p-Value r p-Value
LA Volume ml/m2 0.46 0.0004 0.33 0.01 0.32 0.01
Mean ± SD
IVS thickness 0.001 0.5 0.001 0.5 0.07 0.3
Mean ± SD
E/A: Mean ± SD 0.59 0.000001 0.58 0.00001 0.74 0.000001
Average (e): Mean ± SD 0.67 0.000001 0.57 0.00001 0.59 0.000002
E/e: Mean ± SD 0.86 <0.000001 0.86 <0.000001 0.89 <0.000001
790 A.M. Rawy, D. Fathalladysfunction) 21 patients (58.3%) (Table 4). The present study
showed that patients with severe and very severe grade III and
IV COPD patients have statistically signiﬁcant higher LA vol-
ume values, lower E/A ratio, lower average e values and lower
E/e ratio if compared with patient grade I, II COPD (Table 5).
Also this study demonstrates that these echo variables have
statistically signiﬁcant correlations with FEVI and the average
e values correlate the best with FEVI (Table 6). The inﬂamma-
tory markers serum CRP, MMP-9, TIMP-1 and MMP-
9/TIMP-1 ratio also showed statistically signiﬁcant correla-
tions with both of FEVI and echo Doppler variables of
LVDD, the E/e ratio correlates the best with MMP9, the ratio
of MMP9/TIMP1 and TIMP-1. All this ﬁndings suggest that
prevalence of LVDD is associated with increased disease sever-
ity according to GOLD classiﬁcation and the presence of
inﬂammatory markers serumMMP-9 and TIMP-1. One expla-
nation for this association between disease severity and dias-
tolic function could be systemic inﬂammation. Inﬂammation
is considered to be one of the systemic manifestations of
COPD and provides an alternative hypothesis for explaining
the relationship between airﬂow limitation and atherosclerotic
plaque formation, which are two factors that are also associ-
ated with myocardial ischemia and left ventricular diastolic
dysfunction. Furthermore, the presence of cor pulmonale sec-
ondary to pulmonary hypertension can lead to interventricular
septum deviation toward the left ventricle, which alters left
ventricular geometry and delays ﬁlling [43]. This mechanism
could also explain why disease severity was associated with
worse diastolic function. The cause of increased systemic
inﬂammatory markers in COPD patients might be due to sys-
temic hypoxia which is observed in patients with COPD, due
to deterioration of lung function [44]. However, systemic
hypoxia will usually occur only in severe disease.
In agreement with our results Godoy et al. [29] showed
higher prevalence of LVDD among COPD patients which isassociated with increased disease severity, but the prevalence
was higher 88%, they did not use tissue Doppler which is more
accurate in diagnosis of LVDD, they did not study the inﬂam-
matory serum marker relation to the disease severity, and also
in our study we exclude patients with known hypertension or
uncontrolled diabetes which may provide another etiology to
LVDD rather than disease severity [29].
Ying sum et al., recently studied the impact of COPD on
LVDD but in elderly > 65 years old where they were in con-
cordance with our results they observed high frequency
LVDD in COPD patients 65.5% but against our results they
found no differences among different disease stages, that the
LVDD is not associated with the disease severity, this may
be explained that they included elderly patient > 65 years
old who already may have some degree of diastolic dysfunc-
tion regardless of the disease severity [39].
Williams MJ et al., found also similar results as regards
relation of MMP-9 to the development of left ventricular dias-
tolic dysfunction as they found elevated active MMP-9 level is
associated with more severe LVDD in patients with CAD and
preserved systolic function, which may indicate abnormal
extracellular matrix metabolism in myocardial ischemia [45].Limitations
The major limitations of the present study are the small sample
size of the included patients, lack of the control group, single
center experience.
Conclusions
In conclusion there is a high prevalence of LVDD in COPD
patients which is associated with increased disease severity
according to GOLD classiﬁcation and with the presence high
Left ventricular diastolic dysfunction in patients with COPD 791levels of inﬂammatory markers (serum MMP-9 and TIMP-1),
t is important to exclude decompensated heart failure during
COPD exacerbation.
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